A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Abroad (travel likely)RecruitingPHASE2

Conditions

Minimal Residual Disease · Adjuvant Chemotherapy · Colorectal Cancer · Fruquintinib · Tislelizumab · ctDNA

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

MD Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Arvind Dasari, MD) · giclinicaltrials@mdanderson.org · 713-792-2828
Contact: Principal Investigator (Arvind Dasari, MD)

Study leads

Arvind Dasari, MD
Principal Investigator
M.D. Anderson Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)

Colorectal Cancer · Stage III Colon Cancer · Minimal Residual Disease

Abroad (travel likely)Recruiting

Montpellier, France

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

Metastatic Bone Sarcoma · Metastatic Malignant Neoplasm in the Lung · Metastatic Soft Tissue Sarcoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Buffalo, United States

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Juvenile Myelomonocytic Leukemia · Recurrent Acute Biphenotypic Leukemia · Recurrent Acute Undifferentiated Leukemia

Abroad (travel likely)RecruitingPHASE1

Seattle, United States

Discontinuation Study

Multiple Myeloma · Cancer · Hematologic Cancer

Abroad (travel likely)Recruiting

Cork, Ireland